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The epithelial inner layer of the lower urinary tract, i.e. the urothelium, and other parts of the 
mucosa are not just a passive barrier but play an active role in the sensing of stretching, 
neurotransmitters, paracrine mediators, hormones and growth factors and of changes in the 
extracellular environment. We review the molecular and cellular mechanisms enabling the 
urothelium to sense such inputs and how this leads to modulation of smooth muscle contraction 
and relaxation. The urothelium releases various mediators including ATP, acetylcholine, 
prostaglandins, nitric oxide and nerve growth factor. These may affect function and growth of 
smooth muscle cells and afferent nerves. However, the molecular identity of the urothelium-
derived mediator directly modulating contractile and relaxant responses of isolated bladder 
strips has remained elusive. The morphology and function of the urothelium undergo changes 
with ageing and in many pathophysiological conditions. Therefore, the urothelium may 
contribute to the therapeutic effects of established drugs to treat lower urinary tract dysfunction 
and may also serve as a target for novel therapeutics. However, therapeutics may also change 
urothelial function, and it is not always easy to determine whether such changes are part of the 
therapeutic response or reflect secondary alterations. 
 










EFS, electrical field stimulation 
H2S, hydrogen sulphide 
LUT, lower urinary tract 
NGF, nerve growth factor 
NO, nitric oxide 
NOS, NO synthase 
OAB, overactive bladder syndrome 
PG, prostaglandin   
TRP, transient receptor potential channel 





The urothelium is the epithelial inner layer of the hollow organs of the lower urinary tract 
(LUT). While it has long been considered as a passive barrier only, we now know that it is 
anything but. Firstly, it is much less of a barrier than anticipated and several xenobiotics can be 
absorbed upon intravesical installation to reach systemically relevant concentrations even in 
healthy animals (Krege et al., 2004). Second, the urothelium can become leaky under 
pathophysiological conditions (Parsons, 2011). Third, and most importantly, the urothelium is 
a highly active cell layer, which senses external stimuli, releases various mediators and thereby 
modifies smooth muscle tone and the function of other cell types in the bladder wall. We here 
review the role of the urothelium as a sensor, its modulation of LUT smooth muscle tone, the 
mediators involved in such modulation and the regulation of urothelial function in disease and 
upon treatment. We explicitly wish to refer readers to excellent previous reviews of various 
aspects of urothelial function (Apodaca et al., 2007, Birder and De Groat, 2007, Birder and 




The urothelium is part of the mucosa, which also includes the basal membrane and the lamina 
propria. The latter is a complex structure including afferent nerve endings, interstitial cells 
similar to those of Cajal in the gut, blood and lymphatic vessels and, in some species including 
humans, a muscularis mucosae (Andersson and McCloskey, 2014, Fry and Vahabi, 2016). 
Although the urothelium is only part of the mucosa, some authors have used the terms 
‘urothelium’ and ‘mucosa’ as synonyms, and it is not fully clear from reading the respective 
papers what exactly has been studied. Specifically, ‘urothelium removal’ (for instance to study 
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the role of urothelium-derived mediators on contraction and relaxation) appears to reflect 
removal of the entire mucosa in many cases. Possibly inappropriate use of terms should be 
considered when interpreting published data on the role of the urothelium in particular and of 
the mucosa in general. A summary of key advantages and limitations of various ways to study 
urothelial function and role is given in Table 1. 
 
Studies on the function of the urothelium rely on a range of approaches, each of them having 
specific advantages and limitations. For instance, in vitro studies with bladder strips have often 
applied direct comparisons of strips after removal of the urothelium or entire mucosa with intact 
strips (see sections on modulation of contractile and relaxant responses). Differences between 
the two preparations point to the urothelium or mucosa as being involved; however, it does not 
always become clear whether the urothelial part is in the sensing of the signal and/or the 
response to it. As there are no approaches to remove the urothelium in vivo, conclusions about 
its function in a living animal or patient are difficult. A possible alternative, at least in 
experimental animals, are studies in which a gene of interest is knocked-out or overexpressed 
selectively in the urothelium (Schnegelsberg et al., 2010). 
 
Given these limitations, some investigators have turned to freshly prepared urothelial cells, 
primary cultures thereof or to urothelium-derived cell lines. Such cell lines can be immortalized 
such as the non-malignant cell lines UROtsa or TERT-NHUC cells but can also originate from 
urothelial cancer such as J82 cells. However, the quantitative and qualitative expression pattern 
of urothelial cells may change in culture, and such changes may be even more extensive in 
urothelium-derived cell lines (Tyagi et al., 2006), and even more so in cell lines derived from 
urothelial cancer. Both conclusions were substantiated by later studies exploring a greater 
variety of receptors and other signaling-related molecules (Ochodnicky et al., 2012, Bahadory 
et al., 2013). As the main limitation of freshly prepared urothelial cells is the availability of 
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large quantities, various attempts have been made with rat (Kurzrock et al., 2005) and human 
urothelial cells (Daher et al., 2004) to improve culturing methods, for instance by using matrices 
or organ-like culture. Nonetheless, the interpretation of data from cultured urothelial cells or 
urothelium-derived cell lines needs to consider phenotypic changes, which may limit the 
translational value of these models. 
 
Other limitations exist that are not specific for research on the urothelium. The presence of 
receptors, channels and other molecules can be assessed and quantified at the mRNA level with 
relative ease; however, it remains unclear for most genes how predictive mRNA levels are for 
those of functional protein. Detection at the protein level has been based on radioligand binding 
in some studies on muscarinic receptors (Mansfield et al., 2005, Braverman et al., 2007, 
Anisuzzaman et al., 2008, Mansfield et al., 2009) but has relied additionally (for muscarinic 
receptors) and predominantly (for other receptors) on antibodies. Of note, the vast majority of 
antibodies against G protein-coupled receptors and ligand-gated ion channels lacks useful target 
specificity (Michel et al., 2009) but some carefully validated receptor antibodies are emerging 
(see below). While radioligands allow a more definitive detection of receptors, the ligands used 
for discrimination of subtypes typically had only moderate selectivity. Thus, either method has 
limitations that need to be considered.  
 
Finally, the presence of a given protein or other molecule does not necessarily demonstrate that 
it is involved in a given functional response. Dissection of pathways leading to functional 
responses requires use of activators or, even better, inhibitors of specific steps leading from 
sensing of signal to cellular response. Such dissection can be done using genetic tools, such as 
siRNA, antibodies or small molecules; again, each of these tools comes with its own limitations 




Urothelium as sensor 
 
The physiological amount of urine in the bladder immediately after a void is close to 0 ml in 
humans but may be higher in species using urine for territorial marking behavior such as dogs. 
On the other hand, the healthy human bladder can store about 500 ml, which means that it 
undergoes major stretching during the micturition cycle. This requires sensing mechanisms that 
inform the brain about the filling state of the bladder and allow it to decide whether to continue 
storing or to void. The urothelium appears to play a central role in such sensing. It is also 
involved in the sensing of thermal and chemical stimuli (Birder and Andersson, 2013). Such 
sensing involves various ion channels and receptors and leads to the release of mediators such 
as ATP, acetylcholine (Ach) and nitric oxide (NO, see below). For instance, stretching can 
stimulate the release of mediators including Ach (Yoshida et al., 2006) and ATP (Ochodnicky 
et al., 2013) from the urothelium. Stretch-induced release can further be augmented by 
mediators such as bradykinin (Ochodnicky et al., 2013). 
 
Urothelial cells express a range of cation channels. These include the transient receptor potential 
channels (TRP) TRPV1 and TRPV4. Expression of TRPV1 protein was reportedly greater in 
the superficial than in the basal cells, and much less expression was found in malignant tissue 
(Lazzeri et al., 2005). In contrast, TRPV4 was preferentially found close to adherence junctions, 
with similar expression in healthy and malignant human tissue and in healthy mice (Janssen et 
al., 2011). Such TRP channels are likely to be involved in the sensing of stretching and some 
pathophysiological conditions of the bladder (Nilius and Szallasi, 2014). The urinary bladder 
also expresses several big, small and intermediate conductance Ca2+-activated K+ channels 
(Chen et al., 2004), but at least for the SK2 channel expression appears to exist at a lower level 
in urothelium as compared to bladder smooth muscle (Thorneloe et al., 2008). A difference in 
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contractile responses in the presence of the K+ channel opener rimalkalim in the absence and 
presence of urothelium in mouse, pig and human bladder strips (Wuest et al., 2005), has been 
taken as indirect evidence for a functional role of K+ channels in the urothelium (although these 
experiments most likely reflect a role in the mucosa in general). In line with this caveat, direct 
evidence for a functional role of KCNQ channels in the interstitial cells of the lamina propria 
has been obtained in guinea pigs (Anderson et al., 2009).  
 
The urothelium does not only sense filling of the bladder, but can also sense presence of 
surrounding neurotransmitters, paracrine mediators and hormones. The primary physiological 
transmitter of the parasympathetic nerves innervating the human bladder is Ach (ATP may be 
a primary physiological parasympathetic transmitter in several non-human mammals; 
(Burnstock, 2014)). Moreover, Ach can be formed non-neuronally in the urothelium (Yoshida 
et al., 2006). Some studies have demonstrated expression of some subtypes of nicotinic Ach 
receptors at the mRNA level. In mice, α2, α4, α5, α6, α7, α9 and α10, but not α3 subunits were 
detected; while α9 was found only in the umbrella cells, α4, α7 and α10 subunits were also see 
in the intermediate and basal cell layers (Zarghooni et al., 2007). The same group reported that 
the α7 subunit was much more abundant than the α9 and α10 subunits in human urothelium 
(Bschleipfer et al., 2007). However, most studies have explored the presence of muscarinic Ach 
receptors in the urothelium. Muscarinic receptors have been detected in the urothelium of every 
mammalian species investigated, including mouse (Zarghooni et al., 2007), rat (Cheng et al., 
2007, Anisuzzaman et al., 2008), guinea pig (Grol et al., 2009), pig (Bahadory et al., 2013) and 
man (Mansfield et al., 2005, Tyagi et al., 2006, Braverman et al., 2007, Bschleipfer et al., 2007, 
Mansfield et al., 2009, Ochodnicky et al., 2012). Studies in rat, pig and human have consistently 
reported a lower expression of muscarinic receptors in urothelium than in detrusor (Mansfield 
et al., 2005, Tyagi et al., 2006, Braverman et al., 2007, Cheng et al., 2007, Anisuzzaman et al., 
2008, Bahadory et al., 2013); the sub-urothelial layer also stained positive for muscarinic 
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receptors, but other parts of the lamina propria did not (Grol et al., 2009, Bahadory et al., 2013). 
The most abundantly expressed subtypes at the mRNA and protein level appear to be M2 and 
M3 receptors (Braverman et al., 2007, Bschleipfer et al., 2007, Anisuzzaman et al., 2008, 
Ochodnicky et al., 2012), but some subtypes may exhibit a rather restricted expression with M1 
restricted to basal cells, M2 largely to umbrella cells, M3 and M4 homogenously distributed and 
M5 exhibiting a decreasing expression from luminal to basal (Bschleipfer et al., 2007). 
However, most of these findings were generated with antibodies shown to lack proper target 
selectivity (Jositsch et al., 2009). As most clinically used muscarinic antagonists exhibit 
moderate selectivity for one subtype at best, the clinical relevance of differential expression of 
muscarinic receptor subtypes within the mucosa remains to be elucidated. 
 
Adrenoceptors are also expressed and functionally active in the urothelium. β-Adrenoceptor 
subtype mRNA is present in the urothelium of rats (Kullmann et al., 2011) and humans (Otsuka 
et al., 2008, Tyagi et al., 2009a, Ochodnicky et al., 2012), and in human urothelium-derived 
cell lines (Harmon et al., 2005). The studies providing quantitative evaluation suggest that the 
β2-adrenoceptor subtype is expressed most prominently in both species (Kullmann et al., 2011, 
Ochodnicky et al., 2012). Expression of all three β-adrenoceptor subtypes at the protein level 
has been reported based on immunohistochemistry in humans (Otsuka et al., 2008, Kullmann 
et al., 2011, Otsuka et al., 2013), but only some of these studies have applied validated 
antibodies. However, it is notable that the staining was more intense in urothelium than in 
smooth muscle in all of these studies, which is opposite to the expression pattern of muscarinic 
receptors (see above). One study reported that interstitial cells exhibit less expression than 
urothelium, but more than bladder smooth muscle (Otsuka et al., 2013). α1-Adrenoceptors have 
low abundance in the overall human or porcine bladder (Goepel et al., 1997), and in situ 
hybridization experiments did not detect α1A-adrenoceptor subtype mRNA in human 
urothelium (Walden et al., 1997); the same study however, reported a high density in the 
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urothelium of rat and monkey bladder. An expression profiling study in freshly prepared human 
urothelial cells reported lack of mRNA for α1B-, moderate amounts of α1A- and strongest 
abundance of α1D-adrenoceptors (Ochodnicky et al., 2012). In contrast, the same study detected 
all three subtypes of α2-adrenoceptors. α1D-Adrenoceptors were also detected by immunoblots 
in rat urothelium (Ishihama et al., 2006), albeit based on a non-validated antibody. 
 
Presence of a wide range of other receptors has been explored in isolated studies. For instance, 
freshly isolated human urothelial cells expressed mRNA for serotonin 5HT2A but not 5HT1B 
receptors, angiotensin II type 1 but not type 2 receptors, high levels of endothelin ETA and ETB 
receptors and of all five subtypes of sphingosine-1-phosphate receptors as well as the 
sphingosine kinases 1 and 2 generating their ligand based on array technology (Ochodnicky et 
al., 2012) but not verified by PCR based on validated primers. Bradykinin B1 and B2 receptor 
mRNA was found in human urothelial cells (Ochodnicky et al., 2012); in contrast, only B2 
mRNA was present in normal rat urothelium but B1 receptors became detectable in 
cyclophosphamide-induced cystitis (Chopra et al., 2005). Another study at the whole bladder 
level, found up-regulation of B1 receptor mRNA upon spinal cord injury; immunohistochemical 
experiments showed an increased expression of B1 receptor protein in the urothelium (Forner 
et al., 2012), but this was based on antibodies without proper validation. Freshly isolated human 
urothelial cells expressed mRNA for substance P (NK1), substance K (NK2) and neuromedin 
K receptors (Ochodnicky et al., 2012). Pig bladder has a similar expression of substance K 
receptor mRNA in smooth muscle and suburothelium with less but detectable expression in the 
urothelium (Bahadory et al., 2013). P2Y6 receptor mRNA is also found in the urothelium but 
at lower abundance than in suburothelium and smooth muscle, whereas P2X1 mRNA is only 
present in suburothelium and smooth muscle and not in urothelium. While prostaglandin EP1 
receptors exhibited only weak staining in urothelium and suburothelium of the guinea pig 
bladder, strong staining of EP2 receptors was found in both layers, albeit on limited validation 
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of the antibodies being used (Rahnama'i et al., 2010). Cannabinoid CB1 and CB2 receptor 
mRNA was found in human urothelium, possibly with higher expression than in smooth muscle 
(Tyagi et al., 2009b). The expression level of CB1 appeared higher than that of CB2, and this 
was confirmed in a study of freshly isolated human urothelial cells (Ochodnicky et al., 2012).  
 
Nerve growth factor (NGF) is a key modulator of bladder function (Ochodnicky et al., 2011). 
Urothelium produces and releases NGF (see below) and expresses receptors for it. Freshly 
isolated human urothelial cells expressed mRNA for its low-affinity receptor p75 and, to a lesser 
extent, for the high-affinity receptor trkA (Ochodnicky et al., 2012). Immunohistochemical 
studies confirmed strong expression of p75 in human urothelium (Vaidyanathan et al., 1998, 
Eryildirim et al., 2006), albeit with poorly validated antibodies. 
 
Modulation of contractile responses 
 
Alongside the sensory functions, it has become clear that the urothelium has a local and direct 
influence on the contractility of the underlying smooth muscle in the lower urinary tract. This 
modulatory action was initially demonstrated as an inhibitory effect on bladder detrusor 
contractility, and was first reported in the guinea pig bladder, in which substance P-induced 
contractions were enhanced in mucosa-free bladder strips compared to their mucosa-intact 
counterparts (Maggi et al., 1987). Thereafter, this inhibitory effect of the urothelium on detrusor 
smooth muscle contraction has been reported in bladders from many species, including mouse 
(Wuest et al., 2005, Meng et al., 2008, Canda et al., 2009), guinea pig (Guan et al., 2014), cat 
(Levin et al.), dog (Saban et al., 1992), pig (Hawthorn et al., 2000, Buckner et al., 2002, 
Sadananda et al., 2008) and human (Chaiyaprasithi et al., 2003, Wuest et al., 2005, Propping et 
al., 2013). In 2000, Hawthorn et al., confirmed, using a bioassay experiment in which a 
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urothelium-intact strip was co-incubated with a denuded strip, that the inhibitory effect was due 
to a diffusible urothelium-derived inhibitory factor (UDIF) which was released from the pig 
bladder urothelium (Hawthorn et al., 2000). The effect observed is an inhibition of contractions 
rather than a direct relaxation. Although unidentified in nature, UDIF was released in response 
to muscarinic stimulation, but not in response to elevated extracellular KCl or neurokinin A 
(Hawthorn et al., 2000). Muscarinic-receptor mediated release of the inhibitory factor is 
consistent across most species, apart from dog (Saban et al., 1992). However, an inhibitory 
effect of the urothelium has also been demonstrated following stimulation with KCl in the 
mouse (Wuest et al., 2005), cat (Levin et al.) and human bladder (Wuest et al., 2005, Propping 
et al., 2013), in response to ATP in the cat bladder (Levin et al.), and in response to neurokinin 
A in the dog bladder (Saban et al., 1992) and following nerve-stimulation in cat (Levin et al.) 
and human bladder (Chaiyaprasithi et al., 2003). Thus, the stimulus for release may be species 
dependent. Moreover, a species-specific controversy appears to exist in the rat bladder with 
respect to UDIF. Some studies have shown that the urothelium does not appear to have an 
inhibitory effect on smooth muscle contractility in the rat bladder (Pinna et al., 1992), whilst 
others have used a gentle swabbing technique to remove only the urothelial layer and found an 
inhibitory effect (Munoz et al., 2010).  
 
Although some early reports demonstrated a non-adrenergic, non-nitrergic, non-prostanoid 
relaxation factor in the rat bladder, this was shown to be urothelium-independent (Fovaeus et 
al., 1999, Bozkurt and Sahin-Erdemli, 2004). Adding to the complexity, the rat bladder the 
urothelium releases prostaglandins that excite and contract the bladder, rather than inhibit 
contractions (Nakahara et al., 2003).  
 
Most studies of the inhibitory effect of the bladder urothelium have been performed on the 
bladder dome, but  the urothelium of the bladder trigone has a similar inhibitory effect on 
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smooth muscle contractility, and whilst release of the inhibitory factor is stimulated by 
muscarinic, and histamine, receptor activation  in this region, it is not seen following stimulation 
of α1-adrenoceptors with phenylephrine (Templeman et al., 2002). However, complex cross-
talk appears to occur between the receptor systems, since an inhibition of phenylephrine-
mediated contractions is observed following muscarinic or histamine receptor stimulation.  
 
In addition to the large voiding contractions evoked by motor nerves, which initiate bladder 
emptying, the bladder also demonstrates spontaneous contractile activity which is non-neuronal 
in origin. Whilst the role of this spontaneous activity in bladder function, and the cellular origin, 
is a focus of ongoing research, the urothelium can modulate spontaneous activity in a dramatic 
way. Removal of the urothelium from bladder wall preparations significantly reduced 
spontaneous contractions in the guinea pig (Sui et al., 2008) and rat bladder (Kanai et al., 2007). 
This is in complete contrast to the inhibitory action of the urothelium on tonic contractions 
described above. In contrast, in the mouse bladder the frequency of nifedipine-sensitive 
spontaneous activity of detrusor increased when the urothelium was removed (Meng et al., 
2008) and a similar finding was reported in pig bladder (Buckner et al., 2002). The findings in 
pig bladder show that removal of the urothelium delays development of spontaneous 
contractions in the dome, although not in the trigone, but does not influence frequency of 
amplitude of spontaneous contractions (Akino et al., 2008). Thus, the modulatory effect of the 
urothelium on bladder spontaneous contractility is still a matter of debate. Either way, whilst 
still far from being understood, it has been proposed that the urothelium may have a dual effect 
on contractility, an inhibitory influence on tonic contractions via a diffusible agent and an 
excitatory influence on spontaneous contractility via direct cellular interaction with underlying 
cells, potentially the interstitial cells in the lamina propria (Birder et al., 2010, Fry and Vahabi, 




It is easy to see how the inhibitory influence of the urothelium on bladder tonic contractility 
may be important for normal bladder compliance, since during filling intravesical pressure 
remains low until the initiation of tonic contractions and voiding. With respect to the 
stimulatory action on spontaneous activity, this may reflect a mechanism whereby the bladder 
is maintained at its smallest volume during filling, to optimize sensation of bladder filling.  
 
Whilst the urothelium lines the urinary tract from the renal pelvis through to the upper urethra 
and even the glandular portions of the prostate, there has been limited focus and much less is 
known about the influence of the urothelium on the smooth muscle of the non-bladder regions 
of the LUT. In the urethra, the urothelium changes from a transitional epithelium to become 
stratified or columnar (Romih et al., 2005). However, an inhibitory influence of the urothelium 
on smooth muscle contractility has been demonstrated in the urethra, similar to that observed 
in the bladder. The urothelium of the urethra inhibits noradrenaline-induced contractions, but 
not cholinergic contractions in the hamster (Pinna et al., 1992), contractions to phenylephrine, 
high KCl and nerve-stimulation in the cat (Levin et al.), and bradykinin-induced contractions 
in the pig bladder neck (Ribeiro et al., 2014). We have recently shown that the pig urethra 
releases a diffusible inhibitory factor which reduces contractions to carbachol, noradrenaline 
and phenylephrine by similar amounts (Figure 1). 
 
<<<insert Figure 1 approximately here>>> 
 
Even less well researched is the urothelium of the ureter, although recent evidence suggests that 
it can influence the underlying smooth muscle in a manner similar to that seen in the bladder 
dome, trigone and urethra (Roedel et al., 2018).The urothelium in the human ureter can inhibit 
tonic, but not spontaneous or KCl-stimulated contractions. In the rat ureter the urothelium acts 
to prevent spontaneous contractile activity and also decrease potential excitatory effects of 
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endogenous contractile agents including carbachol, bradykinin and angiotensin II on ureteral 
motility (Mastrangelo and Iselin, 2007). This effect appears to be via the release of a relaxing 
agent rather than an inhibitory factor, although responses to NKA and vasopressin were 
enhanced by urothelium denudation. (Mastrangelo and Iselin, 2007). 
 
Modulation of relaxant responses 
 
In addition to the inhibitory actions on contractility of LUT smooth muscle described above, 
the urothelium is also able to modulate relaxation responses. Although fewer studies have 
investigated this effect, when compared to the number of studies on the inhibitory effects of the 
urothelium on contraction, the evidence has led to the proposal of the release of a urothelial-
derived mediator that is excitatory. Alternatively, the effect may be explained by a direct 
excitatory cellular interaction of the urothelium with underlying cell types. Regardless of the 
underlying mechanism, the evidence highlights the multiple roles that the urothelium seems to 
play in smooth muscle modulation.   
 
Relaxing effects of catecholamines are blunted by the presence of the urothelium in the human 
bladder (Otsuka et al., 2008, Propping et al., 2013, Propping et al., 2015b) and are mediated via  
β2-adrenoceptors (Propping et al., 2013). A similar effect was seen in mouse bladder, and the 
urothelium reduced the sensitivity of KCl pre-contracted tissues to β-adrenoceptor-induced 
relaxation to isoprenaline, again via β2-adrenoceptors, although at high concentrations of 
isoprenaline there was a minor involvement of β3-adrenoceptors (Propping et al., 2015a). Whilst 
in human bladder this inhibitory effect on relaxations was seen in tissues pre-contracted with 
KCl and carbachol (Propping et al., 2015b), the same authors showed in mouse bladder that the 
urothelium did not inhibit relaxations if the tissues were pre-contracted with carbachol 
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(Propping et al., 2015a). The rat bladder urothelium does not appear to influence smooth muscle 
relaxation to β3-adrenoceptor agonists (Kullmann et al., 2011). Interestingly, in the pig bladder, 
we have shown that whilst relaxation responses to isoprenaline are not modulated by the 
urothelium, the urothelium is involved in mediating inhibitory effects of isoprenaline on 
cholinergic detrusor contractions, with isoprenaline being more potent at inhibiting carbachol-
induced contractions when the urothelium is present (Murakami et al., 2007, Masunaga et al., 
2010). This effect was mediated by the β3-adrenoceptor (Masunaga et al., 2010). 
 
Evidence is also conflicting with regard to the role of the urothelium in modulation of non-
receptor mediated relaxations of the bladder smooth muscle. The urothelium does not modulate 
relaxations to the KATP channel opener rimalkalim in the mouse, pig or human bladder (Wuest 
et al., 2005). Although, in contrast, we have also shown that the urothelium does inhibit the 
relaxant effects of cromakalim on spontaneous contractions of the pig bladder dome, but not in 
the trigone region (Akino et al., 2008), suggesting that the mechanism for generation of 
spontaneous contractions in the smooth muscle involves modulation by the urothelium in the 
dome, though not in the trigone. 
 
There is very limited information on the modulatory effect of the urothelium on relaxations of 
the non-bladder regions of the lower urinary tract. Prostaglandin (PG) E2 and 2-methyl-thio-
ATP-induced relaxations of hamster urethra do not seem to be modulated by the urothelium 
(Pinna et al., 1996). However, relaxation responses of hamster urethra to electrical field 
stimulation (EFS) are absent if the urothelium is present, demonstrating an inhibitory 
modulation of nerve-mediated relaxations, which is absent if L-NAME and suramin was present 
(Pinna et al., 1996). However, this appears to be species dependent, since EFS-induced 
relaxations were not affected by the presence of an intact urothelium in the cat urethra (Levin 




In conclusion, the urothelium acts as a sensor for changes in bladder volume, neurotransmitters, 
pH, temperature and various chemicals. In turn it influences smooth muscle activity, inhibiting 
muscle contraction to many stimuli and also inhibiting some relaxation responses of the 
detrusor. These effects of the urothelium on smooth muscle occur following the release of a 
number of mediators, some of which are well documented (e.g. ATP), whilst others have yet to 
be identified (e.g. UDIF). 
Known mediators released from urothelium 
 
The urothelium  releases a wide variety of signalling molecules ranging from the classic 
neurotransmitter Ach to the more recently recognised gaseous transmitter hydrogen sulphide 
(H2S). The release of some of these substances is well documented and their actions on other 
tissues such as sensory nerves well established.  However, our knowledge of their actions on 
smooth muscle is limited. The actions of exogenously administered factors can be readily 
demonstrated in many cases, but very few studies have examined whether factors released from 
the urothelium reach the detrusor muscle at quantities large enough to modulate smooth muscle 
tone and contractions.  Research in this field has increased enormously in recent years. 
However, the findings are complex, since many studies have been performed on bladder strips 
and bladder wall sections, as well as in whole bladders, which invariably contain additional 
non-urothelial cellular elements within the lamina propria or suburothelium. Thus, it is difficult 
to rule out mediator release from other cell types, but  studies on isolated urothelial cells and 
cell lines are helping to clarify findings somewhat.  Evidence for urothelial release and smooth 
muscle action will now be considered individually for each proposed mediator. 
 




Stretch-induced release: ATP release from the urothelium was first described by Fergusson et 
al. (Ferguson et al., 1997) and it is now the most researched signalling molecule released by the 
urothelium. Human urothelial cell lines, both of malignant (RT4 cells) and immortalised but 
non-malignant origin (UROtsa and TRT-HU1), spontaneously release ATP and this is greatly 
enhanced during cellular stretch most commonly induced by osmotic swelling in hypotonic 
solution (Sun and Chai, 2006, Birder et al., 2013, Mansfield and Hughes, 2014a, Mansfield and 
Hughes, 2014b, Kang et al., 2015, Sano et al., 2016, Farr et al., 2017). Similarly, findings have 
been reported for primary cultures of urothelial cells from the guinea pig (McLatchie and Fry, 
2015), cat (Birder et al., 2003) and pig (Cheng et al., 2011b).  
 
In isolated tissue strips, mechanical stretch induces release of ATP from guinea pig (Young et 
al., 2012, Sui et al., 2014), pig (Kumar et al., 2004, Sadananda et al., 2012, Smith et al., 2014, 
Kang et al., 2015) and human bladder (Kumar et al., 2007, Kumar et al., 2010, Sui et al., 2014, 
Sano et al., 2016), while mechanical force induces release in guinea pig urothelial cells 
(Kullmann et al., 2008b). In vivo release of ATP into the bladder lumen has been documented 
for the rat and human bladder (Jeremy et al., 1987, Timóteo et al., 2014). In isolated tissue 
studies, removal of the epithelium from rat bladder strips by swabbing prevents ATP release 
indicating that the urothelium is the sole source of ATP in this species (Munoz et al., 2010). In 
contrast, the release of non-neuronal ATP is not restricted to the urothelium in the pig bladder, 
but also occurs from interstitial cells in the lamina propria and also from the smooth muscle. 
However, the majority of ATP release during stretch still occurs from the urothelial cells 
(Cheng et al., 2011a).  Thus, ATP may be released from non-neuronal, non-urothelial sources 




Chemical-induced release: In addition to stretch, a number of drugs are known to induce ATP 
release including β-adrenoceptor agonists (Birder et al., 2002b), substance P (Munoz et al., 
2010), pituitary adenylate cyclase activating polypeptide (PACAP) (Girard et al., 2008), 
TRPV1 agonists (Birder et al., 2002a) and also some cytokines such as epidermal growth factor 
and anti-proliferative factor (Sun et al., 2009). Muscarinic agonists also stimulate release of 
ATP, the response mediated via the M2 receptor subtype, at least in the guinea pig (Munoz et 
al., 2010, Sui et al., 2014). Sui et al. (2014) found that ATP itself can exert an autocrine action, 
enhancing further ATP release via the activation of P2Y6 receptors. 
 
Mechanisms of ATP release: The release of classic transmitters from nerves involves the 
fusion of storage vesicles with the plasma membrane. However, the release of ATP from the 
urothelial cells appears to be more complex. A number of toxins that prevent the exocytotic 
release of transmitters have been used to address this question and the studies have become 
more clinically relevant as these toxins increasingly become available to treat the overactive 
bladder (Chancellor, 2017). Rat and human urothelial cells possess the protein target SNAP-23 
and SNAP-25 for botulinum toxin, and treatment of urothelial cells with this toxin reduces the 
release of ATP and surprisingly increases release of NO (Hanna-Mitchell et al., 2015). The 
contrasting effects of the toxin on ATP and NO release confirmed a previous study in the rat, 
in which these changes in urothelial mediators were associated with changes in afferent nerve 
activity (Collins et al., 2013). These reports support the concept of vesicular release of ATP 
from urothelial cells, but botulinum toxin also exerts other effects such as a reduction in P2X3 
and TRPV1 receptors that may alter urothelial function (Apostolidis et al., 2006). Furthermore, 
evidence is mounting that other mechanisms may be operating in the urothelium. Recently 
pannexin channels, which have been demonstrated to have a role in the non-neuronal release of 
ATP in non-urinary tissues, have been identified in urothelial cells (Negoro et al., 2014). 
Inhibitors of these channels reduce ATP release in the rat bladder and depress release from 
20 
 
human urothelial cells, while mice lacking these channels also exhibit reduced ATP release 
from the urothelium (Negoro et al., 2014, Beckel et al., 2015, Silva et al., 2015). In anaesthetised 
rats, stimulation of P2Y6 receptors causes release of urothelial ATP and increases voiding 
frequency, but inhibition of pannexin channels reverses both the change in ATP release and the 
bladder overactivity (Timóteo et al., 2014). Silva et al. (Silva et al., 2015) confirmed that this 
purinergic autocrine action mediated via P2X6 receptors occurs via pannexin channels rather 
than vesicular release. 
 
ATP release induced by stretch also involves pannexin channels with inhibitors of these 
channels reducing ATP release in rat and human urothelium (Negoro et al., 2014). Other 
channels have also been linked to ATP release and urothelial cells from mice lacking P2X7 
channel receptors (Negoro et al., 2014) or mechanosensitive Piezo channels (Miyamoto et al., 
2014) exhibit reduced ATP release. Thus, ATP release appears to involve a number of 
mechanisms covering vesicular release and release via channels. It seems likely at this stage 
that both mechanisms operate to enable ATP release. 
 
Functions of urothelial ATP: In recent years, growing evidence supports the role of urothelial 
derived ATP in mechanosensation. It is now generally accepted that bladder filling results in 
stretch of the urothelium stimulating the release of ATP, which acts on suburothelial sensory 
nerves to signal bladder fullness to the CNS. All aspects of this transduction system have been 
explored and confirmed: ATP is released during urothelial stretch, P2X3 receptors are present 
on sensory nerves (Lee et al., 2000), stimulation of which activates bladder sensory nerves. 
Furthermore, bladder dysfunction has been observed in P2X2/3 gene knock out animals 
(Cockayne et al., 2000, Vlaskovska et al., 2001, Cockayne et al., 2005). Another autocrine 
action has also been reported where ATP via P2X receptors regulates endocytosis and 
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exocytosis to control urothelial surface area as the bladder stretches (Truschel et al., 2002, 
Wang et al., 2005). 
 
However, it is less clear whether urothelium-derived ATP can directly influence smooth muscle 
contraction. Detrusor smooth muscle expresses P2X1 purinoceptors, and exogenous ATP 
induces contraction of the smooth muscle in animals (Lee et al., 2000) and in human bladder 
(Harvey et al., 2002). However, evidence that endogenous ATP from the urothelium influences 
smooth muscle contraction is scarce, although in guinea pig bladder strips with an intact 
urothelium, carbachol enhances spontaneous contractile activity at low concentrations that have 
no effect when applied directly to the muscle (Sui et al., 2014). Since ATP is known to regulate 
this activity and carbachol induces release of ATP from the urothelium, the results suggest that 
low dose carbachol may induce contractile activity indirectly via urothelial ATP release. This 
conclusion is further supported by the finding that P2X receptor desensitisation also prevented 
the spontaneous activity (Sui et al., 2014). 
 
Another mechanism by which urothelial ATP may influence detrusor activity is via 
suburothelial interstitial cells, which possess multiple purinergic receptor subtypes. In the 
human bladder both P2X1 and P2X3 receptors have been identified on the interstitial cells where 
they modulate cell spontaneous activity (Cheng et al., 2011b). These cells are coupled to each 
other and smooth muscle via gap junctions (Ikeda et al., 2007) and thus the initial signal of ATP 
release may be transported deep into the smooth muscle following a local effect on interstitial 
cells. 
 
Thus, in conclusion, the release of ATP from the urothelium has been demonstrated in all 
species so far studied. The stimuli for release includes stretch, shear stress, cholinergic, 
adrenergic and tachykinin receptor stimulation. There is also a purinergic autocrine feedback 
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mechanism enhancing release. The function of ATP in mechanosensation is well established, 
but it also influences smooth muscle spontaneous contractile activity. Release of ATP into the 
urine of patients during bladder filling has been shown, although in this study ATP release 
appeared to occur early in filling with quite low bladder volumes (Jeremy et al., 1987, Cheng 





A non-neuronal cholinergic system exists within the urothelium, and Ach release has been 
widely demonstrated in mouse, pig, guinea pig and human bladder urothelium preparations 
(Lips et al., 2007, Nile and Gillespie, 2012, Smith et al., 2014), human bladder strips (Yoshida 
et al., 2006, Bschleipfer et al., 2012, Silva et al., 2015), as well as in isolated rat (Hanna-Mitchell 
et al., 2007), guinea pig (Kullmann et al., 2008b) and human urothelium cells (Kang et al., 2013, 
Li et al., 2013, Farr et al., 2017).  
 
Whilst the urothelium can synthesize and release Ach, the mechanisms by which it does so are 
very different to those seen in cholinergic neurons. The presence of high-affinity choline 
transporter CHT1 and Ach-synthesizing enzyme choline acetyltransferase is controversial 
(Yoshida et al., 2006, Hanna-Mitchell et al., 2007, Yoshida et al., 2008, Bschleipfer et al., 
2012), and it has been proposed that ACh is synthesized in the urothelium predominantly by 
the enzyme carnitine acetyltransferase (Lips et al., 2007). In terms of stimulus for release, both 
mechanical stress (McLatchie et al., 2014) and stretch of the urothelium (Yoshida et al., 2006, 
Hanna-Mitchell et al., 2007, Nile and Gillespie, 2012, Kang et al., 2013, Farr et al., 2017) can 
evoke Ach release, and, at least in cells, this seems to be an all-or-nothing event, rather than 
related to degree of stress (McLatchie et al., 2014). ATP is a potent chemical stimulus for Ach 
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release  (Hanna-Mitchell et al., 2007, Stenqvist et al., 2017) and this is mediated partly by P2Y6 
receptors in the human bladder (Silva et al., 2015), and PGE2 also stimulates Ach release (Nile 
and Gillespie, 2012). 
 
The mechanism by which Ach is released from urothelial cells does not involve vesicular 
exocytosis (Hanna-Mitchell et al., 2007, Lips et al., 2007, Bschleipfer et al., 2012), and is 
independent of extracellular calcium, connexins and pannexins. Instead, the anion channel 
CFTR, intracellular calcium (Bschleipfer et al., 2012), and the organic cation transporters OCT1 
and OCT3 play a role (Hanna-Mitchell et al., 2007, Lips et al., 2007, Bschleipfer et al., 2012).  
 
Autocrine and paracrine ACh signaling occurs within the urothelium, although the precise role 
in normal bladder function is not yet clear. Ach can act via a negative feedback mechanism to 
inhibit further Ach release from the urothelium (Hanna-Mitchell et al., 2007) whilst, in contrast, 
muscarinic receptor agonists evoked Ach release from primary human bladder urothelial cells 
(Li et al., 2013). Adding to the complexity, Ach causes release of ATP from the urothelium 
(Kullmann et al., 2008a, McLatchie et al., 2014) and might also indirectly affect the release of 
NO, tachykinins and prostanoids (Hanna-Mitchell et al., 2007, Kullmann et al., 2008b, Nile and 
Gillespie, 2012). The question of whether urothelial Ach directly contracts bladder smooth 
muscle was recently partly addressed by Stenqvist et al. (2017), who showed that ATP 
stimulates release of urothelial Ach, which contributes to purinergic contractile responses of 
the rat bladder.  
 
Whilst our understanding of non-neuronal Ach in the urothelium of the bladder has increased, 
Ach in the urothelium within the remainder of the LUT is a relatively untouched area of 
research. So far, the only evidence comes from a study of the urothelium of the rat urethra, 
which can release Ach from specialized polymodal urethral chemosensory cells (urethral brush 
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cells) in response to stimulation of bitter receptors and a cholinergic negative autocrine 
feedback mechanism for Ach release appears to exist in this tissue (Deckmann et al., 2018). 
 
In conclusion, Ach is released from urothelial cells and the mechanism of choline uptake, Ach 
synthesis and Ach release differ from those involved in neuronal cholinergic systems. There is 
some evidence for urothelial Ach having actions on smooth muscle but this is limited and 
requires further study. 
 
Nitric oxide (NO) 
 
NO is a gaseous transmitter with inhibitory functions in most systems of the body. It is formed 
from L-arginine by NO synthases (NOS). These enzymes exist intracellularly as three different 
isoforms: two calcium-dependent constitutively expressed forms, endothelial NOS (eNOS) and 
neuronal NOS (nNOS) and one calcium-independent inducible form (iNOS), which is 
expressed under some conditions such as inflammation (Birder et al., 2005). The main form 
present in the healthy urothelium has been shown to be nNOS in several animal species 
including the rat (Birder et al., 2002b, Chuang et al., 2013), guinea pig (Gillespie et al., 2005) 
and cat (Theobald, 2003), while eNOS has been identified in the rat bladder (Giglio et al.). It 
has been suggested that eNOS is the only form present in the healthy human bladder (Fathian-
Sabet et al., 2001), but others have found it in the urothelium and the interstitial cells of the 
lamina propria of the human bladder (De Ridder et al., 1999). Furthermore, iNOS is up-
regulated in bladder cancer (Lin et al., 2003) and can be induced during inflammatory 
conditions such as interstitial cystitis (Birder et al., 2005, Andersson et al., 2012) and following 
treatment with lipopolysaccharide (Weng et al., 2009). A reduction in nNOS and simultaneous 
increase in iNOS in urothelial cells has been observed in an obstructed bladder outlet model in 
the rat (Johansson et al., 2002a). These changes in NOS are likely related to inflammation and 
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the release of cytokines that have been shown to enhance NOS expression (Johansson et al., 
2002b). 
 
A number of stimuli causing non-neuronal NO release has been identified and these include 
capsaicin, a TRPV1 receptor agonist which stimulates release from the mucosa and sensory 
nerves (Birder et al., 1998), β-adrenoceptor agonists (Birder et al., 2002b) and substance P 
(Munoz et al., 2010). The latter study also showed that the NO originated in the lamina propria 
rather than the urothelial cells. 
 
The role of NO of neuronal origin in the bladder outlet is well established where it relaxes the 
smooth muscle during voiding, thus preventing any large rise in luminal pressure (Andersson 
and Persson, 1994). The role of NO of mucosal origin is difficult to determine due to the 
multiple sources of NO within the bladder including the urothelium and interstitial cells within 
the lamina propria (Munoz et al., 2010) and due to its multiple action that include modulation 
of afferent nerve function activity (Aizawa et al., 2011) and influences on smooth muscle and 
interstitial cell function (Gillespie et al., 2004). Surprisingly, detrusor muscle itself is not very 
sensitive to NO, and NOS inhibitors have little effect on the contractions of the detrusor smooth 
muscle induced by muscarinic agonists or nerve stimulation (Frazier et al., 2005). Inhibition of 
NO synthase enhances contraction amplitude in response to EFS (Garcia-Pascual et al., 1991), 
while NO donors induce detrusor smooth muscle relaxation in precontracted tissues (Hernández 
et al., 2008). However, the effect on detrusor smooth muscle is small compared to the effects 
of NO on vascular smooth muscle. Even when comparing the effect on detrusor to its actions 
on the bladder outlet region, the influence of NO on detrusor contraction is relatively minor 
(Kedia et al., 2009). Furthermore, in the normal rat bladder, NOS inhibition has little or no 
effect on detrusor contractile responses to muscarinic stimulation (Andersson et al., 2008, 




However, NO appears to play a far more significant role during inflammation. In the rat bladder 
during inflammatory responses induced by cyclophosphamide, the mucosa exerts a 
considerable (25%) inhibitory effect on detrusor contraction, and muscarinic responses are 
enhanced when the mucosa is removed. This inhibitory effect in this situation can be reversed 
in the presence of a NOS inhibitor (Andersson et al., 2008).  Thus, it appears that muscarinic 
agonists induce a direct stimulatory effect on smooth muscle, which is partly reversed by NO 
release from the mucosa in inflammatory states. 
 
The actions of NO are mediated via cGMP; the targets of NO action have been identified by 
examining cGMP immunoreactivity after stimulation of the bladder with NO donors and these 
include detrusor smooth muscle, urothelial and interstitial cells (Fathian-Sabet et al., 2001, 
Gillespie et al., 2006). It has been suggested that it is the interstitial cells within the 
suburothelium that are most sensitive to urothelial NO rather than the smooth muscle (Gillespie 
et al., 2005). These interstitial cells are thought to relay information from the urothelium to the 
smooth muscle and thus provide an indirect mechanism by which NO may influence smooth 
muscle contraction. Another indirect mechanism is via effects on smooth muscle growth, since 
NO donors have an inhibitory effect on the proliferation of smooth muscle cells (Johansson et 
al., 2002a). 
 
Thus, NO appears to have only a minor direct role in regulating smooth muscle contraction but 
may influence muscle tone indirectly by modulating interstitial cells in the suburothelium, 
which in turn may influence smooth muscle tone. Since the actions of NO are mediated via 
cGMP and are inhibitory to cells, this indirect action may possibly explain the excitatory effects 
that are occasionally observed in bladder. Although the vast majority of reports concerning NO 
have indicated that it exerts inhibitory actions on smooth muscle, there is also some evidence 
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to suggest that NO can exert excitatory effects. In the isolated mouse bladder, NO can increase 
phasic contractile activity (Gillespie and Drake, 2004) and in pre-contracted human detrusor 
strips, both relaxation and contraction responses to NO donors have been observed (Moon, 
2002). 
 
In conclusion, the role of NO in the bladder is complex.  It is released from multiple sites and 
has multiple targets of action.  Furthermore, this complex role appears to change in disease 
states following the induction of iNOS.  
 
Other gaseous transmitters 
 
In addition to NO, there are two other gaseous transmitters, H2S and carbon monoxide. 
Although there is currently no evidence for the urothelium releasing carbon monoxide, several 
studies have examined the H2S systems in the bladder. Surprisingly, most of the studies have 
been performed on human tissues and cells. The human urothelium possesses the H2S 
synthesising enzymes, cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE). These 
enzymes catalyse the conversion of L-cysteine to H2S and both enzymes have been located to 
the urothelium of the human bladder dome (Fusco et al., 2012). Also, the H2S precursor L-
cysteine relaxes human bladder strips, an effect that is blocked by inhibitors of CBS and CSE 
(Fusco et al., 2012). Furthermore, in human cultured T24 urothelial cells, stimulation with 
carbachol causes the release of H2S and again this is prevented in the presence of a CBS 
inhibitor. The release of H2S induced by carbachol in human T24 urothelial cells was mediated 
via the activation of M1 and M3 muscarinic receptors (d’Emmanuele di Villa Bianca et al., 
2016). It is still early days in the study of H2S, but the functions of H2S in the bladder appears 
two-fold: an autocrine effect on the urothelium and an inhibitory effect on the detrusor muscle. 
H2S appears to exert an autocrine effect by elevating intracellular cGMP levels in urothelial 
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cells, the consequences of which are yet to be established (d’Emmanuele di Villa Bianca et al., 
2016). However, sildenafil increases H2S release suggesting that cGMP is involved in a positive 
feedback mechanism regulating H2S release. Sildenafil also causes bladder relaxation and both 
responses (increased H2S and bladder relaxation) are reduced by inhibitors of CBS and CSE 
(Fusco et al., 2012). Further evidence for an action on smooth muscle has come from isolated 
tissue experiments, again on human tissues, where inhibition of H2S synthesis does not impact 
detrusor contractions to carbachol directly, but does enhance bladder contractions when the 
urothelium is present (d’Emmanuele di Villa Bianca et al., 2016). Thus, H2S appears to be 
released from the urothelium and exert at least two effects, enhancement of H2S release and 




Prostanoid production in the bladder wall is well established, with prostanoids known to be 
synthesized locally within both the mucosa and smooth muscle and they are thought to play a 
role in the sensory arm of the micturition reflex. Urothelial production of prostanoids has been 
demonstrated in the bladder of most species including rat (Pinna et al., 1992, Masunaga et al., 
2006, Tanaka et al., 2011), rabbit (Masick et al., 2001, Azadzoi et al., 2004), guinea pig (Saban 
et al., 1994, Nile et al., 2010, Guan et al., 2014) and human (Jeremy et al., 1987). Cyclo-
oxygenase 1 is markedly localized to the urothelium and expressed within the basal and 
intermediate cells (de Jongh et al., 2009), although not in the umbrella cells (Rahnama’i et al., 
2012).  Interestingly, production of prostaglandins by the urothelium is far greater than in the 
suburothelium and smooth muscle (Masick et al., 2001, Azadzoi et al., 2004). The 
prostaglandins released are those known to be both excitatory and inhibitory in nature within 




Release of prostaglandins from the bladder urothelium is induced by stretch and bladder 
distension (Downie and Karmazyn, 1984, Jeremy et al., 1987, Tanaka et al., 2011, Farr et al., 
2017), although this may vary with pathology since PGE2 release is not stretch-related in 
urothelial cancer RT4 cells (Kang et al., 2013). ATP, Ach and NO also regulate PGE2 release 
in a complex signaling interaction which sees ATP (Nile et al., 2010) and Ach (via M2 
receptors) (Nile and Gillespie, 2012) stimulate prostaglandin release, whilst NO has a negative 
feedback effect on cholinergic release of PGE2 (Nile et al., 2010). 
 
Evidence for a direct influence of urothelially-released prostaglandins on the underlying smooth 
muscle was provided in a study by Nakahara et al., who showed that activation of protease-
activated receptor-2 can stimulate release of prostaglandins from the rat bladder mucosa to 
contract the detrusor smooth muscle (Nakahara et al., 2003). 
 
In summary, a number of prostaglandins are released by the urothelium, with some excitatory 
and some inhibitory to smooth muscle.  Considering the complex pathways, multiple 
prostaglandins and many receptors by which these mediate responses, it is surprising how few 
studies appear in the literature. 
 
Peptides & cytokines 
 
The urothelium is also a source of inflammatory peptides and cytokines, with mediators of 
inflammation such as substance P stimulating the release of NGF and macrophage migration 
inhibitory factor (Meyer-Siegler and Vera). The release of interleukins (IL-1β, IL-6, IL-8) has 
also been observed in several human urothelial cell lines including RT4, T24 and UROtsa cells 
following treatment with cytotoxic drugs which induce an inflammatory response (Kang et al., 
2015, Farr et al., 2017). Also, in the rat, inflammation of the bladder induced by treatment with 
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cyclophosphamide results in the release of the cytokines IL-6 and leukemia inhibitory factor 
and ciliary neurotrophic factor (Girard et al., 2011). These factors released from the urothelial 
cells will have localized effects, but their potential effects on smooth muscle are unknown.  It 
is unlikely NGF will have direct effects on smooth muscle contraction, since over-expression 
of this peptide in mice does not appear to influence the efferent arm of the micturition reflex 
(Girard et al., 2012). However, NGF may influence detrusor responses indirectly by altering 
receptor expression in smooth muscle, since urothelium-specific over-expression of NGF in 
mice reduces smooth muscle VPAC1 receptor transcripts, the receptor for vasoactive intestinal 
peptide (Girard et al., 2010). Another indirect effect of NGF on contraction may be to alter 
muscle mass since NGF increases expression of IGF-1 in isolated detrusor smooth muscle cells. 
Furthermore, after in vivo cyclophosphamide treatment of mice which causes muscle 
hypertrophy, the administration of NGF-neutralising antibody reverses the hypertrophy induced 
by CPO (Zhang and Qiao, 2012). The effects of these inflammatory mediators obviously require 
further investigation. 
 
In summary, the known mediators released from the urothelium include ATP, Ach, 
prostaglandins, several peptides and the gaseous transmitters NO and H2S. Various interactions 
modify release of these chemicals which complicates studies.  A variety of actions have been 
demonstrated for most of these known mediators, but for each the evidence to support actions 








Despite the number of mediators and neurotransmitters now known to be released from the 
urothelium, evidence as to whether any of these may act to directly influence the underlying 
smooth muscle of the lower urinary tract is limited, as mentioned above for each mediator. In 
particular, attempts to elucidate the nature of the UDIF modulating smooth muscle contractility 
in the bladder and urethra have been unsuccessful. In the pig bladder, the inhibitory effect of 
the urothelium is not due to the release of NO, nor is the UDIF a cyclo-oxygenase product, a 
catecholamine, adenosine, GABA or an endothelium-released hyperpolarizing factor sensitive 
to apamin.  It is also not affected by antagonists at P1 or P2 purinergic receptors (Hawthorn et 
al., 2000).  Involvement of NO, cyclo-oxygenase products, and β-adrenoceptors were similarly 
ruled out as candidates for the UDIF in the human bladder (Chaiyaprasithi et al., 2003), and in 
the guinea bladder the inhibitory factor is not NO, is not mediated by adenosine receptors nor 
is it a cyclo-oxygenase product (Guan et al., 2014). Similarly in the urethra the urothelial 
inhibition is independent of NO (Pinna et al., 1992) and cyclo-oxygenase products (Folasire et 
al., 2017). 
 
In the rat, exogenous ATP suppresses detrusor contractions in a manner similar to that seen in 
the presence of the mucosa (Santoso et al., 2010), but there is no direct evidence that 
endogenous ATP inhibits contraction and purinergic antagonists such as suramin do not prevent 
the inhibitory effect of the mucosa in the pig bladder (Hawthorn et al., 2000). In contrast, in the 
rat ureter the inhibitory action of the urothelium, which prevents spontaneous contractile 
activity and decreases excitatory effects of carbachol, bradykinin and angiotensin II on ureteral 
motility, appears to involve cyclo-oxygenase products, which may activate the release of a 
relaxing factor (Mastrangelo and Iselin, 2007). Additionally, in the hamster urethra, NO and 




In terms of the putative excitatory factors released from the urothelium, which act to inhibit 
relaxations of the smooth muscle, these seem to be prostanoid in nature (Nakahara et al., 2003).  
However, in the human bladder angiotensin and neurokinin pathways may also be involved 
(Propping et al., 2015b), and in the pig bladder neck BK channels may play a role (Ribeiro et 
al., 2014). Thus, the nature of the urothelium-derived agents that have been shown to modulate 
smooth muscle in the lower urinary tract appear to be complex and are still far from being 
understood. 
 
Pathophysiology of the urothelium 
 
Based on the role of the urothelium in sensing the cellular environment and releasing mediators 
to modify it, several investigators have explored alterations of a wide range of parameters 
related to the morphology and function of the urothelium (Table 2). Such investigations were 
reported for various species including mouse (Daly et al., 2014) (Pak et al., 2010), rat 
(Johansson et al., 2002a, Afiatpour et al., 2003, Liu and Daneshgari, 2006, Doyle et al., 2018) 
(Eika et al., 1993, Haefliger et al., 2002, Pitre et al., 2002, Murray et al., 2004, Chopra et al., 
2005, Tong et al., 2006, Barendrecht et al., 2007, Cheng et al., 2007, Tong and Cheng, 2007, 
Andersson et al., 2008, Hanna-Mitchell et al., 2013, Coelho et al., 2015, Xiao et al., 2015) 
(Andersson et al., 2008), rabbit (Santarosa et al., 1994, Azadzoi et al., 1999, Azadzoi et al., 
2010) and human (Lowe et al., 1997, Vaidyanathan et al., 1998, Mansfield et al., 2005, Datta 
et al., 2010, Kumar et al., 2010, Munoz et al., 2011, Bschleipfer et al., 2012, Kurizaki et al., 
2013, Ballouhey et al., 2015), as well as in vitro with cell lines derived from human urothelium 
(Kang et al., 2015). They involved a range of conditions including ageing (Afiatpour et al., 
2003, Mansfield et al., 2005, Daly et al., 2014), overactive bladder syndrome (OAB)/idiopathic 
detrusor overactivity (Datta et al., 2010, Kumar et al., 2010, Munoz et al., 2011), neurogenic 
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voiding dysfunction (Vaidyanathan et al., 1998, Datta et al., 2010, Ballouhey et al., 2015, Doyle 
et al., 2018), chronic pelvic ischemia (Azadzoi et al., 1999, Azadzoi et al., 2010), bladder outlet 
obstruction (Santarosa et al., 1994, Haefliger et al., 2002, Johansson et al., 2002a, Barendrecht 
et al., 2007, Bschleipfer et al., 2012, Kurizaki et al., 2013), diabetes (Eika et al., 1993, Pitre et 
al., 2002, Liu and Daneshgari, 2006, Tong et al., 2006, Cheng et al., 2007, Tong and Cheng, 
2007, Pak et al., 2010, Hanna-Mitchell et al., 2013, Xiao et al., 2015), and cystitis (Lowe et al., 
1997, Sun et al., 2009), the latter mostly in the context of cyclophosphamide treatment (Murray 
et al., 2004, Chopra et al., 2005, Andersson et al., 2008, Coelho et al., 2015) (Andersson et al., 
2008). Of note, it is not necessarily the abundance of a given factor but rather its ratio with that 
of other factors that may be of importance (Yoshida et al., 2004, Munoz et al., 2011, Silva et 
al., 2015). However, very few combinations of species, conditions and outcome parameters 
have been studied more than once, which makes it difficult to determine the robustness of any 
of the reported alterations.  
 
These reports clearly demonstrate that the morphology and function of the urothelium is 
dynamically regulated in disease. Such alterations could plausibly contribute to the 
pathophysiology of bladder dysfunction and deserve additional investigation. While it is 
frequently speculated that such alterations could relate to the pathophysiology of the disease 
under investigation, it remains uncertain in most cases whether they are a consequence or a 
cause of alterations of the urothelium in disease. An example for this is the finding of a 
correlation between urothelial expression of α1-adrenoceptors and symptom severity in men 
with benign prostatic hyperplasia (Kurizaki et al., 2011).  
 






A limited number of studies have explored how common treatments of OAB may affect the 
urothelium. Muscarinic receptor antagonists inhibit ATP release from human bladder strips, 
which is largely absent after mucosal removal, implying an effect on the mucosa (Yoshida et 
al., 2009). Studies with isolated rat bladder also reported that muscarinic antagonists reduce 
ATP release and extended these findings to release of prostaglandin E2 (Yokoyama et al., 2011). 
Experiments in the human urothelium-derived UROtsa cell line found increased proliferation 
in response to a muscarinic agonist, which was blocked by a muscarinic antagonist (Arrighi et 
al., 2011); such findings could provide a mechanistic explanation to increased urothelial 
thickness in some pathological states (see Table 2). 
 
Botulinum toxin was reported to inhibit ATP release from cultured rat urothelial cells (Hanna-
Mitchell et al., 2015) and also from mouse urothelium in vivo (Collins et al., 2013). In contrast, 
it promoted NO release in the latter model. It attenuated the decrease of urothelial 
immunoreactivity of M1 muscarinic receptors in patients with detrusor overactivity (Datta et 
al., 2010). Botulinum toxin also attenuated the increase in urothelial expression of TRPV1 and 
NGF in rats with bladder outlet obstruction(Ha et al., 2011). In contrast, urothelial NGF 
overexpression in mice leads to neuronal hyperinnervation and changes in bladder function 
(Schnegelsberg et al., 2010). Finally, the purinergic P2Y6 receptor agonist UDP inhibited Ach 







The urothelium plays a central role in the sensing of the filling state of the urinary bladder via 
the presence of neurotransmitters, paracrine mediators, hormones and other constituents of the 
extracellular environment (Figure 2). In response to such inputs, it can release various mediators 
that act in an autocrine and paracrine manner to modulate the function of the urothelium itself, 
but also that of other cells types including smooth muscle and afferent nerves. While the 
presence of the urothelium has proven a strong modulator of detrusor contractility, such an 
influence is apparently not mediated by known factors released from the urothelium. The 
molecular identity of such factors has remained elusive. It may be speculated that it is related, 
if not identical to, endothelium-derived relaxing factors (other than NO) and endothelium-
derived hyperpolarizing factor. The morphology, sensing mechanisms and mediator release 
from the urothelium apparently undergo major changes with ageing, in pathological conditions 
and upon treatment, with the influence of gender also unknown.  However, the evidence is too 
scattered to allow robust conclusions on the nature of these alterations and whether they 
represent causative parts of the pathophysiology or adaptations to an underlying pathology. 
Robust identification of such altereations may lead to urothelium-directed therapeutics, that 
allow a more targeted treatment of bladder dysfunction. 
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Table 1: Model systems to study urothelial function. For details see section on methodological 
considerations in main text. 
 
Model Key advantage Key limitation 
In vivo Physiologically most 
relevant 
Little direct information on 
involvement of urothelium 
in bladder function 
Isolated bladder strips with 
and without 
urothelium/mucosa removal 
Can directly assess 
functional impact of 
urothelium 
Conclusions only indirect by 
comparing absence and 
presence; unclear whether 
removal affects ability to 
sense and/or to respond to 
stimulus 
Freshly isolated urothelial 
cells 
Allows detailed mechanistic 
investigation 
Effects on other cell types 
can only be inferred 
Primary culture and cell 
lines 
Allows mechanistic 
investigation with larger 
quantities of cells 
Expression pattern markedly 






Table 2: Parameters of urothelial morphology and function reported to be altered under 
various conditions. BOO, bladder outlet obstruction; NVD, neurogenic voiding dysfunction; 
OAB, overactive bladder syndrome 
 




rabbit Chronic pelvic 
ischemia 
disturbed (Azadzoi et al., 
1999, Azadzoi et 
al., 2010) 
Apoptosis rabbit BOO increase (Santarosa et al., 
1994) 
Thickness rat BOO increase (Barendrecht et 
al., 2007) 
Cross-sectional area rat diabetes increase (Xiao et al., 2015) 
Umbrella cells rat diabetes desquamation (Hanna-Mitchell 
et al., 2013) 
Bladder function 
Contraction rat spinal cord injury decrease (Doyle et al., 
2018) 
     
Receptor and channel expression 
Muscarinic M1 human OAB/NVD decrease (Datta et al., 2010) 




 rat diabetes increase (Tong et al., 2006, 
Tong and Cheng, 
2007) 
 rat spinal cord injury decrease (Doyle et al., 
2018) 
Muscarinic M3 rat diabetes increase (Cheng et al., 
2007, Tong and 
Cheng, 2007) 
Bradykinin B1 rat cystitis increase (Chopra et al., 
2005) 
Endothelin ETB rat aging decrease (Afiatpour et al., 
2003) 
Purinergic P2X3 mouse aging increase (Daly et al., 2014) 
TRPV1 rat diabetes increase (Hanna-Mitchell 
et al., 2013) 
trkA, trkB rat cystitis decrease (Murray et al., 
2004) 
Mediators 
ATP release human OAB/NVD increase (Kumar et al., 
2010, Munoz et 
al., 2011) 
 human OAB increase (Birder et al., 
2003, Kumar et 
al., 2007) 
 human cystitis increase (Sun et al., 2009) 
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 human Mitomycin C decrease (Kang et al., 2015) 
Acetylcholine human Mitomycin C increase (Kang et al., 2015) 
Prostaglandin E2 human Mitomycin C increase (Kang et al., 2015) 
NO rat cystitis increase (Andersson et al., 
2008) 
Other parameters 








rat BOO decrease (Johansson et al., 
2002a) 
Connexins rat BOO increase (Haefliger et al., 
2002) 
bFGF, TGF rabbit BOO increase (Santarosa et al., 
1994) 
NGF rat cystitis increase (Coelho et al., 
2015) 
 human cystitis increase (Lowe et al., 
1997) 





Legends to the figures 
 
Figure 1: Effects of mucosa denudation on contractile responses of the pig urethra to 
agonists. Cumulative concentration-response curves to carbachol (upper panel, n = 5), 
noradrenaline (middle panel, n = 4) and phenylephrine (lower panel, n = 7) on isolated porcine 
urethral strips prepared either with an intact mucosa (filled circles) or with the mucosa removed 
(open squares). Data are shown as means ± SD. Differences in Emax between intact and 
denuded strips were statistically significant (P < 0.05) in unpaired, two-tailed t-tests. Adapted 





Figure 2: Neurotransmitter and hormonal inputs to the urothelium and outputs to the 
smooth muscle.  The urothelium has receptors for a wide variety of transmitters including nerve 
growth factor (NGF), prostaglandins (PG), acetylcholine (Ach), substance P (SP), neurokinin 
A (NKA), adenosine triphosphate (ATP), 5-hydroxytryptamine (5HT), noradrenaline (NA), 
bradykinin (BK), capsaicin (Cap), angiotensin II (AG), cannabinoids (CB) and endothelin (ET).  
In response to these inputs, the urothelium releases a number of chemical mediators including 
ciliary neurotrophic factor (CNF), macrophage migration inhibitory factor (MIF), leukocyte 
inhibitory factor (LIF), hydrogen sulphide (H2S), urothelium-derived inhibitory factor (UDIF), 
and interleukins (IL). These actions of these mediators on smooth muscle can be excitatory [+], 
inhibitory [-] or unknown [?]. 
 
 
 
 
